My prescriber ordered three tests and this board recommends about twenty, and I would like to know which of those two lists is right.
What I am trying to establish is what actually belongs on a baseline panel, as opposed to the enormous list that gets pasted around here.
I would rather have one careful answer than five confident ones.
Taking the question as asked, rather than the general version of it. The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value. One out-of-range result in isolation generates anxiety and unnecessary tests; the same result next to the trend and the rest of the panel usually generates a shrug.
SarahChen_PharmD said:The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value.
SarahChen_PharmD has the substance of this right. The condition it depends on is worth stating. One addition: if the lab changes analytical platform between your draws, the comparison breaks and nobody tells you. It is worth asking when a value moves inexplicably.
That is the short version; the long version is somebody else's post.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsSaraMom3 said:My prescriber ordered three tests and this board recommends about twenty, and I would like to know which of those two lists is right.
This matches mine closely enough to be worth saying so. Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c becomes informative again, since it reflects about three months of glycaemia. After the first year, and once doses are stable, annual is reasonable unless something specific is being followed.
From the other side of the consultation, briefly.
Blood work came back perfect. baseline bloodwork + this community = winning. 🏆